MEPs closer to agreement on EU patient information proposal
This article was originally published in Scrip
The European Parliament is drawing nearer to agreement on the controversial EU proposal to allow pharmaceutical companies to provide drug information to patients. But the final result is likely to be a very watered down version of the European Commission's original proposal, with regulators exerting tight control over the narrow range of information materials that companies will be able to provide.
You may also be interested in...
The UK has used a special legislative process to temporarily authorize the use of the BNT-162b2 vaccine, with the first 800,000 shots expected to be delivered within days.
A package of health proposals intended to build up the EU’s resilience to health threats while strengthening the competitiveness of Europe’s pharmaceutical industry and ensuring access to affordable drugs takes a major step through the legislative process this week.
European Commission proposals for strengthening intellectual property protections in the EU, particularly the supplementary protection certificate (SPC) system, have been broadly welcomed by Europe’s brand industry. But the medical NGO, MSF, says the SPC proposals run counter to the commission’s own efforts to improve access to medicines.